Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data to Develop Dx to Predict Response Rate for Rituximab

NEW YORK (GenomeWeb News) — Clinical Data plans to develop a molecular diagnostic aimed at identifying patients likely to respond to a monoclonal antibody made by Genentech/Biogen-Idec and Roche
The deal calls for Clinical Data to measure patient response to rituximab, which is used to treat non-Hodgkins lymphoma and rheumatoid arthritis. The company reported yesterday that it has signed a licensing agreement for “an extensive portfolio of patents” toward this goal, but would not disclose the name of the licenser.
Clinical Data said the diagnostic will employ a variation in the FCGRIIIA gene, which will have a greater than 90-percent specificity in predicting response to rituximab in NHL.
The company also expects that this gene will be useful in measuring response to other monoclonal antibodies used to treat Crohn’s disease and other inflammatory disorders.

Genentech recently licensed a gene map of Crohn’s disease from Genizon Biosciences.



CD said it expects to begin working on the rituximab diagnostic in early 2007.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more